Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pfizer acquires Wyeth in $67bn deal

Executive Summary

In a cash and stock transaction, Pfizer is buying Wyeth for $66.7bn. Shareholders get $50.13--$33 in cash and $17.13 in Pfizer common stock--for each Wyeth common share (a 29% premium). Pfizer is funding the transaction with help from a bank consortium that committed $22.5bn in debt.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies